Abstracts Archive - Page 357 of 2607 - ACR Meeting Abstracts

Abstract Number: 0685 • ACR Convergence 2024
KL-6 and IL-18 Biomarkers in Systemic Sclerosis-associated Interstitial Lung Disease: Enhancing Prognostic Insights into Early Detection, Progression, Lung Volume Changes,and Mortality Risk
cristiana sieiro santos¹, Miriam Retuerto², Laura Sierra², Sara Calleja Antolín², Elena Bollo de Miguel², Jose Ordas Martínez³, Paula Pérez García², Pedro Baenas², Clara Moriano Morales², Javier de la Calle Lorenzo² and Elvira Díez Álvarez⁴, ¹Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain, ²Complejo Asistencial Universitario de León, León, Spain, ³Complejo Asistencial Universitario de Leon, Leon, ⁴Complejo Asistencial Universitario de León, Leon, Spain
Background/Purpose: Interstitial lung disease (ILD) is a leading cause of mortality in scleroderma, underscoring the critical demand for reliable biomarkers. KL-6 and IL-18, have been…
Abstract Number: 0714 • ACR Convergence 2024
Therapeutic Dilemmas in Patients with ANCA-associated Vasculitis: Diffuse Alveolar Hemorrhage, Venous Thromboembolism and Anticoagulation
Elif Ediboglu¹, Samuel Falde¹, Misbah Baqir¹, Rodrigo Cartin-Ceba², Robert McBane¹ and Ulrich Specks¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Scottsdale, AZ
Background/Purpose: Diffuse alveolar hemorrhage (DAH) is an acutely life-threating presentation of ANCA-associated vasculitis (AAV), and patients with AAV are at increased risk of venous thromboembolic…
Abstract Number: 0705 • ACR Convergence 2024
Identification of Risk Factors for Incident Cardiomyopathy in Patients with Systemic Sclerosis
Ji Soo Kim¹, Rachel Wallwork¹, Carrie Richardson², Adrianne Woods³, Monica Mukherjee⁴, Steven Hsu⁴, Julie Paik¹, Christopher Mecoli¹, Laura Hummers⁵, Fredrick Wigley⁶, Scott Zeger¹ and Ami Shah⁷, ¹Johns Hopkins University, Baltimore, MD, ²Northwestern University, Chicago, ³Johns Hopkins University Division of Rheumatology, Baltimore, MD, ⁴Johns Hopkins University Division of Cardiology, Baltimore, MD, ⁵Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Ellicott City, MD, ⁶Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Baltimore, MD, ⁷Division of Rheumatology, Johns Hopkins University, Ellicott City, MD
Background/Purpose: Cardiac involvement in systemic sclerosis (SSc) is one of the leading causes of scleroderma-associated death. There are limited data examining risk factors for incident…
Abstract Number: 0698 • ACR Convergence 2024
Association of Systemic Sclerosis with ANCA-Associated Vasculitis and Large Vessel Vasculitis: Impact of Pulmonary Arterial Hypertension
Brett Dinner¹, Ahmed Abdelmaksoud², Ann Igoe³, Taylor Viggiano⁴ and Vivek Nagaraja⁵, ¹Creighton University, Paradise Valley, AZ, ²University of California, Riverside, Riverside, CA, ³Flow, Tempe, AZ, ⁴Mayo Clinic, Phoenix, ⁵Mayo Clinic Arizona, Scottsdale, AZ
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disorder with excessive fibrosis and vasculopathy. While typically non-inflammatory, frank vasculitis can complicate SSc. Concomitant SSc with ANCA-associated…
Abstract Number: 0709 • ACR Convergence 2024
Linear Combination of Principal Components Achieves Top Performance in Identifying Rheumatologist-Diagnosed Systemic Sclerosis from Electronic Health Records
Yiming Luo, Gongbo Zhang, Chunhua Weng and Elana Bernstein, Columbia University Irving Medical Center, New York, NY
Background/Purpose: Systemic sclerosis (SSc) is a rare systemic autoimmune rheumatic disease. International Classification of Diseases (ICD) code counts (for example, using ≥ 2 ICD-10 codes…
Abstract Number: 0708 • ACR Convergence 2024
Outcomes of Intermittent Intravenous Steroid Use During Infusion Therapy in Systemic Sclerosis
Vangala Adarsh¹, dihowm Fatma¹, Eyerusalem Akpan², Meredith Keller², Maheswari Muruganandam², N. Suzanne Emil², Frank O'Sullivan³, Roderick Fields² and wilmer sibbitt¹, ¹UNM, Albuquerque, NM, ²University of New Mexico, Albuquerque, NM, ³University of New Mexico School of Medicine, Albuquerque, NM
Background/Purpose: Use of high dose corticosteroids in systemic sclerosis (SSc) is considered a significant risk factor for development of scleroderma renal crisis (SRC). Intravenous (IV)…
Abstract Number: 0701 • ACR Convergence 2024
Diagnostic Performances of Vascular Biomarkers Soluble Fms-like Tyrosine Kinase (sFlt-1) and Placental Growth Factor (PlGF) in Scleroderma Renal Crisis: A Case Control Study
Aïcha Kante¹, Paul Legendre², Bérangère Joly³, bertrand Dunogue⁴, Alexandre Hertig⁵, Benjamin Terrier⁶, Elodie Massolin⁷, Felix Ackermann⁸, Luc Mouthon⁴, Jean Guibourdenche⁹ and Benjamin Chaigne¹⁰, ¹Department of internal medicine, Centre de Compétence Maladies Rares autoimmunes et inflammatoires, Université Paris Cité, Paris, Ile-de-France, France, ²Service immunologie clinique, Centre hospitalier du Mans, Le Mans, France, Le Mans, ³Service d'Hématologie Biologique, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris (APHP.Nord), Université Paris Cité, Paris, Ile-de-France, France, ⁴Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, ⁵Department of Nephrology, Hôpital Foch, Suresnes, France, Suresnes, Ile-de-France, France, ⁶Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France, ⁷UF d'Hormonologie, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (APHP), Paris, Paris, Ile-de-France, France, ⁸Department of Internal Medicine, Foch Hospital, Suresnes, France., Suresnes, France, ⁹APHP-CUP, Hôpital Cochin, F-75014 Paris, Université Paris Cité, Paris, Ile-de-France, France, ¹⁰Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, Ile-de-France, France
Background/Purpose: Scleroderma renal crisis (SRC) is a major vascular complication of systemic sclerosis (SSc), associated with high morbidity and mortality. Few biomarkers are available to predict…
Abstract Number: 0693 • ACR Convergence 2024
Behind the Bronchiectasis in Systemic Sclerosis. Prevalence and Risk Factors
Miriam Retuerto Guerrero¹, Clara Moriano², Paula Perez Garcia³, cristiana sieiro santos⁴ and elvira Diez álvarez³, ¹Complejo Asistencial Universitario de León, Leon, Spain, ²Hospital León, LEON, Spain, ³Complejo Asistencial Universitario de Leon, Leon, ⁴Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain
Background/Purpose: Bronchiectasis (BC) has been observed in association with Systemic Sclerosis (SSc). Esophageal dysmotility, immunosuppressive drugs and the direct effect of collagen deposition in the…
Abstract Number: 0655 • ACR Convergence 2024
Relationship Between Patient-Reported Outcomes to Hospitalization in Patients Living with SLE: A Retrospective Cohort Study Utilizing the FORWARD Lupus Registry
Minjee Park¹, Sofia Pedro², Jean-Francois Ricci¹, Kaleb Michaud³ and Patti Katz⁴, ¹Alira Health, Basel, Switzerland, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³University of Nebraska Medical Center, Omaha, NE, ⁴UCSF, San Rafael, CA
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease with diverse symptoms and multisystemic manifestations. Reducing exacerbations (flares), often leading to hospitalization, remains a challenge…
Abstract Number: 0654 • ACR Convergence 2024
Corneal Confocal Microscopy: An Ophthalmic Imaging Biomarker for Small Fiber Neuropathy in Systemic Lupus Erythematosus
Miral Gharib¹, Georgios Baloglu Baloglu², Soha Osman¹, Rayaz A.Malik³ and Samar Alemadi⁴, ¹hamad medical corporation, Doha, Qatar, ²Weill Cornell Medicine , Qatar, doha, ³Weill Cornell Medicine , Qatar, doha, Qatar, ⁴Hamad medical corporation, Doha, Qatar
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic multi-system autoimmune disease with frequent neuropsychiatric symptoms associated with poor outcomes. Small fiber neuropathy can cause intolerable…
Abstract Number: 0726 • ACR Convergence 2024
Management of ANCA Vasculitis-Associated Orbital Inflammatory Disease: A Systematic Literature Review
Emma Neary¹, Katie Healey², Marie Clements-Baker³, Jean-Paul Makhzoum⁴ and Arielle Mendel⁵, ¹McGill University, Montreal, QC, Canada, ²Memorial University of Newfoundland, St. John's, NL, Canada, ³Queen's University, Kingston, ON, Canada, ⁴Vasculitis Clinic, Canadian Network for Research on Vasculitides, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ⁵McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Ocular manifestations are common in ANCA-associated vasculitides (AAV), with orbital inflammatory disease (OID) representing a significant subset. Despite being a vision-threatening complication, OID remains…
Abstract Number: 0523 • ACR Convergence 2024
Distinct Peripheral Blood Immune Cell Sub-population Signatures at Baseline of Tofacitinib or Adalimumab Initiation Are Associated to Clinical Responses at 6 Months
Panagiota Goutakoli¹, Eirini Sevdali¹, Elpida Neofotistou-Themeli¹, Argyro Repa², Nestor Avgoustidis³, Sofia Pitsigavdaki⁴, Eleni Kalogiannaki², George Bertsias⁵, Nikolaos Paschalidis⁶, Panayotis Verginis⁷ and Prodromos Sidiropoulos⁸, ¹University of Crete, Laboratory of Rheumatology, Autoimmunity and Inflammation, Heraklion, Greece, ²University Hospital, Rheumatology, Clinical Immunology, Heraklion, Greece, ³University Hospital, Rheumatology and Clinical Immunology,, Heraklion, Greece, ⁴Rheumatology and Clinical Immunology, University of Crete School of Medicine, Heraklion, Greece, Heraklion, Greece, ⁵Laboratory of Rheumatology, Autoimmunity and Inflammation. University Hospital, Rheumatology, Clinical Immunology, Heraklion, Greece, ⁶Biomedical Research Foundation, Academy of Athens, Athens, Greece, ⁷Medical School, University of Crete, Heraklion, Crete, Greece, ⁸University of Crete, Laboratory of Rheumatology, Autoimmunity and Inflammation. University Hospital, Rheumatology, Clinical Immunology. Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology, Heraklion, Greece, HERAKLIO, Greece
Background/Purpose: Biomarkers to predict response to tofacitinib or adalimumab are not clinically available. Herein we aimed to characterize peripheral blood immune cell subsets with a…
Abstract Number: 0700 • ACR Convergence 2024
Prospective Evaluation of Capillaroscopy in Healthy Children
Tessa Dufour¹, Maurizio Cutolo², Dieneke Schonenberg-Meinema³, Kaat Wyckstandt⁴, Adela Sarbu⁵, joke dehoorne⁶, Steven Wallaert⁷ and vanessa smith⁸, ¹University Hospital Ghent, Gent, Belgium, ²Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genova, Italy, ³Amsterdam University Medical Center, Amsterdam, Netherlands, ⁴University Hospital Ghent, Ghent, Belgium, ⁵University hospital Bern, Bern, Switzerland, ⁶University Hospital Ghent, Ghent, ⁷Ghent University, Ghent, Belgium, ⁸Ghent University Hospital, Gent, Belgium
Background/Purpose: Capillaroscopy is a well-established tool in the diagnosis of adult-onset rheumatic diseases and global consensus on standardisation of execution and interpretation performing capillaroscopy have…
Abstract Number: 0688 • ACR Convergence 2024
Mycophenolate Mofetil Treatment in Limited Cutaneous Systemic Sclerosis Reduces the Risk of Vascular Complication Leading to Treatment Escalation: Emulation of a Target Trial Using Time-dependent Propensity Score-matching
Enrico De Lorenzis¹, Gerlando Natalello², Fabio Cacciapaglia³, Rossella De Angelis⁴, Edoardo Cipolletta⁵, Veronica Codullo⁶, Giacomo De Luca⁷, Dilia Giuggioli⁸, Francesca Ingegnoli⁹, Valeria Riccieri¹⁰, Maria Antonietta D'Agostino¹¹, Clodoveo Ferri¹², Marco Matucci Cerinic¹³ and Silvia Laura Bosello¹⁴, ¹Catholic University of the Sacred Heart, Roma, Rome, Italy, ²Division of Rheumatology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Rome, Italy, ³Rheumatology Unit � DiMePRe-J, University and AOU Policlinico of Bari, Italy, Bari, Italy, ⁴Polytechnic University of Marche, Ancona, Italy, Ancona, Italy, ⁵Polytechnic University of Marche, Ancona, Italy, ⁶Division of Rheumatology - Policlinico San Matteo, Pavia, Italy, Pavia, Lombardia, Italy, ⁷Vita-Salute San Raffaele University & IRCCS San Raffaele Hospital, Milan, Milan, Italy, ⁸Scleroderma Unit, University of Modena and Reggio Emilia, Modena, Italy, ⁹Division of Clinical Rheumatology, ASST Pini, Dept. of Clinical Sciences & Community Health, Research Center for Adult and Pediatric Rheumatic Diseases, Research Center for Environmental Health, Università degli Studi di Milano, Milan, Italy, ¹⁰Department of Rheumatology, La Sapienza University of Rome, Rome, Italy, ¹¹Division of Rheumatology, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Università Cattolica del Sacro Cuore, Rome, Italy, ¹²Rheumatology Unit, School of Medicine, University of Modena and Reggio Emilia, Modena, Italy, ¹³Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy, ¹⁴Unit of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy
Background/Purpose: The prescription of Mycophenolate Mofetil (MMF) represents the primary treatment for interstitial lung disease (ILD) associated with systemic sclerosis (SSc) and is an option…
Abstract Number: 0561 • ACR Convergence 2024
Axial Spondyloarthritis Patients with Comorbid Fibromyalgia Feel Worse, Work Less and More Often Try Multiple Biological DMARDs − Results from a Population-Based Cohort
Annie Brink¹, Elisabeth Mogard², Elisabet Lindqvist², Jonas Sagard², Johan Karlsson Wallman¹ and Tor Olofsson², ¹Lund University, Department of Clinical Sciences Lund, Section of Rheumatology and Skåne University Hospital, Lund, Sweden, Lund, Skane Lan, Sweden, ²Lund University, Department of Clinical Sciences Lund, Section of Rheumatology and Skåne University Hospital, Lund, Sweden, Lund, Sweden
Background/Purpose: A growing arsenal of biologic/targeted synthetic DMARDs often makes inflammation control an attainable target in axial spondyloarthritis (axSpA). Yet, many patients keep suffering from…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].